TEAM

MANAGEMENT
TEAM

Takahiro Iwamiya Co-Founder / Co-CEO Read more Takahiro Iwamiya Co-Founder / Co-CEO Graduated from Tokyo Women’s Medical University with a Ph.D. in Medicine in March, 2014 From 2010, Taka worked on regeneration of the heart and cardiac fibroblasts at Tokyo Women’s Medical University’s Advanced Biomedical Sciences (TWIns) From 2014, Taka led a research team to create organ tissues with fibroblasts at the Institutes for Advanced Biosciences, Keio University. Taka started to prepare for the launching of Metcela in that same year As a co-founder at Metcela, Taka is responsible for R&D matters

Kenichi Nogami Co-Founder / Co-CEO Read more Kenichi Nogami Co-Founder / Co-CEO Graduated from the University of Tsukuba with a B.A. in International Relations in March, 2008. Ken started the MBA program at UCLA Anderson School of Management in August, 2015 (later dropped out) Began professional career as an investment banker at Sumitomo Mitsui Banking Corporation in 2008 and continued at Morgan Stanley from 2010, Ken cultivated expertise in M&A and equity financing for 6.5 years Since 2014, Ken led the corporate development office at The RealReal Japan, while preparing to launch Metcela with Taka As a co-founder at Metcela, Ken is responsible for all the business initiatives including financing, business model development, partnerships and clinical development strategies

Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine

Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine

Directs the Cardiovascular Stem Cell Laboratory and Stanford Cardiothoracic MRI Program
Research interest focuses on translational effort of iPSC-derived small molecules for cardiovascular restoration
Received BAS and MA from Stanford University and M.D. from Yale University School of Medicine, and completed post-graduate training at UCLA and Stanford University Medical Centers

Program Director (U.S.) Japan Biodesign, Stanford Biodesign, Medicine

Program Director (U.S.) Japan Biodesign, Stanford Biodesign, Medicine

Currently serves as a Chief Medical Officer at Medventure Partners, Inc.
Works as a research associate of cardiovascular medicine at Stanford University where he is responsible for preclinical studies including GLP for medical devices and also regenerative medicines for cardiovascular diseases
Visiting Professor at T-CReDO (Tsukuba Clinical Research & Development Organization) since 2019

President, Anioplex LLC

President, Anioplex LLC

President of Anioplex, LLC, advisor for select companies and organizations
Research expertise in regenerative medicine, stem cells, and gene therapy and biomaterials at Harvard Medical School, Kyoto University and UCLA
Ph.D in Biomedical Engineering from UCLA, J.D. from Santa Clara University with High Tech Law Certificate with corporate specialization and honors